PSPA
MCID: PTT048
MIFTS: 62

Pituitary Adenoma, Prolactin-Secreting (PSPA)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Pituitary Adenoma, Prolactin-Secreting

MalaCards integrated aliases for Pituitary Adenoma, Prolactin-Secreting:

Name: Pituitary Adenoma, Prolactin-Secreting 57 12 13
Prolactinoma 12 53 59 75 55 44 15 73
Prolactin-Secreting Pituitary Adenoma 53 59 75
Prl-Secreting Pituitary Adenoma 53 59
Pituitary Lactotrophic Adenoma 53 59
Lactotroph Adenoma 53 59
Prloma 53 59
Prolactin-Producing Pituitary Gland Adenoma 53
Prolactinoma of Pituitary Gland 12
Prolactinoma, Familial 57
Familial Prolactinoma 12
Pspa 75

Characteristics:

Orphanet epidemiological data:

59
prolactinoma
Inheritance: Not applicable; Prevalence: 1-5/10000 (United Kingdom),6-9/10000 (Belgium),1-5/10000 (Switzerland),1-9/100000 (Malta); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

OMIM:

57
Inheritance:
familial tendency independent of association with men-1


Classifications:



Summaries for Pituitary Adenoma, Prolactin-Secreting

NIH Rare Diseases : 53 Prolactinoma is a tumor of the pituitary gland that causes increased levels of the hormoneprolactin. This hormone normally stimulates breast development and milk production in women. Prolactinoma can affect men or women. In women, the symptoms may include unusual milk production (galactorrhea) when not pregnant or nursing and having no menstrual cycles (amenorrhea). In men, the most common symptoms are decreased sex drive and infertility. Most prolactinomas occur by chance (sporadically) in people with no family history. In a small number of cases, prolactinoma may be caused by a genetic condition such as multiple endocrine neoplasia type 1 (MEN1) or familial isolated pituitary adenoma. Treatment for prolactinoma usually involves taking oral medications known as dopamine agonists. These medications can reduce prolactin levels and shrink the tumor. In more severe cases, radiation therapy or surgery may be needed.

MalaCards based summary : Pituitary Adenoma, Prolactin-Secreting, also known as prolactinoma, is related to prolactin producing pituitary tumor and hyperprolactinemia. An important gene associated with Pituitary Adenoma, Prolactin-Secreting is AIP (Aryl Hydrocarbon Receptor Interacting Protein), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Dopamine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, testes and lung, and related phenotypes are ptosis and diplopia

OMIM : 57 Prolactin-secreting pituitary adenoma, or prolactinoma, is the most common type of hormonally active pituitary adenoma. These tumors can also be seen as a feature of multiple endocrine neoplasia type I (MEN1; 131100). See also 102200 for a discussion of familial isolated pituitary adenoma (FIPA) and acromegaly due to a growth hormone (GH; 139250)-secreting pituitary adenoma, which are also caused by mutation in the AIP gene. Schlechte (2003) discussed prolactinoma in general terms as a clinical, diagnostic, and therapeutic problem. (600634)

UniProtKB/Swiss-Prot : 75 Prolactin-secreting pituitary adenoma: Most common type of hormonally active pituitary adenoma.

Related Diseases for Pituitary Adenoma, Prolactin-Secreting

Diseases related to Pituitary Adenoma, Prolactin-Secreting via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 204)
# Related Disease Score Top Affiliating Genes
1 prolactin producing pituitary tumor 32.0 DRD2 PRL SST
2 hyperprolactinemia 31.9 DRD2 GH1 IGF1 POMC PRL SST
3 pituitary adenoma 1, multiple types 31.6 AIP GH1 IGF1 PRL SST
4 pituitary apoplexy 30.6 AIP POMC PRL
5 gigantism 30.5 AIP GH1 PRL
6 multiple endocrine neoplasia, type i 30.2 GNAS MEN1 PRKAR1A PRL SST
7 carney complex variant 30.2 AIP GNAS MEN1 PRKAR1A
8 galactorrhea 30.1 DRD2 IGF1 PRL
9 insulin-like growth factor i 30.0 GH1 IGF1 PRL SST
10 amenorrhea 30.0 POMC PRL TRH
11 pituitary carcinoma 29.9 GNAS POMC PRL SST
12 empty sella syndrome 29.8 GH1 IGF1 POMC PRL TRH
13 craniopharyngioma 29.8 GH1 IGF1 PRL TRH
14 lymphocytic hypophysitis 29.8 GH1 POMC
15 hypopituitarism 29.8 GH1 IGF1 POMC PRL
16 adenoma 29.8 AIP GH1 GNAS IGF1 MEN1 POMC
17 growth hormone deficiency 29.8 GH1 GHSR IGF1
18 carcinoid syndrome 29.8 IGF1 MEN1 SST
19 primary hyperparathyroidism 29.7 MEN1 PRKAR1A PRL
20 meningioma, familial 29.7 MEN1 SST SSTR2
21 mccune-albright syndrome 29.4 GH1 GNAS IGF1 PRL SST
22 fibrous dysplasia 29.4 GH1 GNAS IGF1 PRL SST
23 hypothyroidism 29.3 GH1 GNAS IGF1 POMC PRL TRH
24 pituitary tumors 29.3 AIP GH1 GNAS IGF1 MEN1 POMC
25 acromegaly 29.3 AIP GH1 GNAS IGF1 MEN1 POMC
26 growth hormone secreting pituitary adenoma 29.0 AIP GHSR GNAS PRKAR1A PRL SST
27 silent pituitary adenoma 10.3 AIP MEN1
28 null pituitary adenoma 10.3 AIP MEN1
29 generalized resistance to thyroid hormone 10.3 PRL TRH
30 familial isolated pituitary adenoma 10.3 AIP CDH23
31 multiple endocrine neoplasia 10.3
32 fibrous dysplasia/mccune-albright syndrome 10.2 GH1 PRL
33 bronchus adenoma 10.2 POMC SST
34 bronchial adenomas/carcinoids childhood 10.2 POMC SST
35 pancreatic somatostatinoma 10.2 MEN1 SST
36 type c thymoma 10.2 SST SSTR2
37 intestinal neuroendocrine benign tumor 10.2 MEN1 SSTR1
38 small intestine neuroendocrine neoplasm 10.2 MEN1 SSTR1
39 schizophreniform disorder 10.2 DRD2 PRL
40 non-functioning pituitary adenoma 10.2 GH1 SST
41 chiasmal syndrome 10.2 POMC PRL SST
42 nelson syndrome 10.2 POMC PRL SST
43 headache 10.2
44 carcinoid tumors, intestinal 10.2 MEN1 SST SSTR2
45 hypothalamic disease 10.2 GH1 POMC PRL
46 sella turcica neoplasm 10.2 POMC PRL
47 serotonin syndrome 10.2 MEN1 SST SSTR1
48 acidophil adenoma 10.1 IGF1 POMC SST
49 sheehan syndrome 10.1 IGF1 POMC PRL
50 suprasellar meningioma 10.1 POMC TRH

Graphical network of the top 20 diseases related to Pituitary Adenoma, Prolactin-Secreting:



Diseases related to Pituitary Adenoma, Prolactin-Secreting

Symptoms & Phenotypes for Pituitary Adenoma, Prolactin-Secreting

Symptoms via clinical synopsis from OMIM:

57
Oncology:
prolactinoma
prolactin-secreting pituitary adenoma


Clinical features from OMIM:

600634

Human phenotypes related to Pituitary Adenoma, Prolactin-Secreting:

59 32 (show top 50) (show all 53)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ptosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000508
2 diplopia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000651
3 osteopenia 59 32 frequent (33%) Frequent (79-30%) HP:0000938
4 seizures 59 32 occasional (7.5%) Occasional (29-5%) HP:0001250
5 hypotension 59 32 frequent (33%) Frequent (79-30%) HP:0002615
6 blindness 59 32 occasional (7.5%) Occasional (29-5%) HP:0000618
7 delayed puberty 59 32 occasional (7.5%) Occasional (29-5%) HP:0000823
8 vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002013
9 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
10 osteoporosis 59 32 frequent (33%) Frequent (79-30%) HP:0000939
11 pallor 59 32 frequent (33%) Frequent (79-30%) HP:0000980
12 progressive visual loss 59 32 frequent (33%) Frequent (79-30%) HP:0000529
13 hypogonadotrophic hypogonadism 59 32 hallmark (90%) Very frequent (99-80%) HP:0000044
14 easy fatigability 59 32 frequent (33%) Frequent (79-30%) HP:0003388
15 male hypogonadism 59 32 hallmark (90%) Very frequent (99-80%) HP:0000026
16 vertigo 59 32 occasional (7.5%) Occasional (29-5%) HP:0002321
17 growth hormone excess 59 32 occasional (7.5%) Occasional (29-5%) HP:0000845
18 gynecomastia 59 32 frequent (33%) Frequent (79-30%) HP:0000771
19 headache 59 32 frequent (33%) Frequent (79-30%) HP:0002315
20 dyspareunia 59 32 frequent (33%) Frequent (79-30%) HP:0030016
21 secondary growth hormone deficiency 59 32 frequent (33%) Frequent (79-30%) HP:0008240
22 impotence 59 32 hallmark (90%) Very frequent (99-80%) HP:0000802
23 galactorrhea 59 32 hallmark (90%) Very frequent (99-80%) HP:0100829
24 decreased fertility in females 59 32 hallmark (90%) Very frequent (99-80%) HP:0000868
25 pituitary hypothyroidism 59 32 frequent (33%) Frequent (79-30%) HP:0008245
26 decreased fertility in males 59 32 hallmark (90%) Very frequent (99-80%) HP:0012041
27 female hypogonadism 59 32 hallmark (90%) Very frequent (99-80%) HP:0000134
28 adrenocorticotropin deficient adrenal insufficiency 59 32 frequent (33%) Frequent (79-30%) HP:0011735
29 adrenocorticotropic hormone deficiency 59 32 frequent (33%) Frequent (79-30%) HP:0011748
30 decreased circulating acth level 59 32 frequent (33%) Frequent (79-30%) HP:0002920
31 bitemporal hemianopia 59 32 occasional (7.5%) Occasional (29-5%) HP:0030521
32 oculomotor nerve palsy 59 32 occasional (7.5%) Occasional (29-5%) HP:0012246
33 amenorrhea 59 32 hallmark (90%) Very frequent (99-80%) HP:0000141
34 cranial nerve vi palsy 59 32 occasional (7.5%) Occasional (29-5%) HP:0006897
35 decreased female libido 59 32 hallmark (90%) Very frequent (99-80%) HP:0030018
36 sudden loss of visual acuity 59 32 occasional (7.5%) Occasional (29-5%) HP:0001117
37 fourth cranial nerve palsy 59 32 occasional (7.5%) Occasional (29-5%) HP:0007011
38 internal ophthalmoplegia 59 32 occasional (7.5%) Occasional (29-5%) HP:0007942
39 abnormality of hair density 59 32 frequent (33%) Frequent (79-30%) HP:0011357
40 nausea and vomiting 59 Frequent (79-30%)
41 cranial nerve paralysis 59 Occasional (29-5%)
42 anterior hypopituitarism 59 Occasional (29-5%)
43 hemianopsia 59 Occasional (29-5%)
44 hypogonadism 59 Very frequent (99-80%)
45 pituitary prolactin cell adenoma 32 HP:0006767
46 abnormality of the menstrual cycle 59 Very frequent (99-80%)
47 erectile abnormalities 59 Very frequent (99-80%)
48 abnormality of the pituitary gland 59 Very frequent (99-80%)
49 low gonadotropins (secondary hypogonadism) 59 Very frequent (99-80%)
50 menstrual irregularities 59 Very frequent (99-80%)

GenomeRNAi Phenotypes related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 10.23 MEN1
2 Decreased viability GR00221-A-1 10.23 PRKAR1A
3 Decreased viability GR00221-A-2 10.23 PRKAR1A
4 Decreased viability GR00221-A-3 10.23 PRKAR1A
5 Decreased viability GR00221-A-4 10.23 PRKAR1A
6 Decreased viability GR00240-S-1 10.23 AIP CORT SST
7 Decreased viability GR00381-A-1 10.23 CORT GHSR GNAS SSTR3 SSTR5 TRHR
8 Decreased viability GR00381-A-2 10.23 CORT GHSR
9 Decreased viability GR00381-A-3 10.23 CORT GHSR
10 Decreased viability GR00402-S-2 10.23 AIP CDH23 CORT DRD2 GH1 GHSR
11 no effect GR00402-S-1 9.62 AIP CDH23 CORT DRD2 GH1 GHSR

MGI Mouse Phenotypes related to Pituitary Adenoma, Prolactin-Secreting:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.28 AIP CDH23 CORT DRD2 GHSR GNAS
2 behavior/neurological MP:0005386 10.27 CDH23 CORT DRD2 GHSR GNAS POMC
3 growth/size/body region MP:0005378 10.24 AIP CDH23 CORT DRD2 GHSR GNAS
4 endocrine/exocrine gland MP:0005379 10.22 AIP CORT DRD2 GNAS IGF1 MEN1
5 adipose tissue MP:0005375 10.02 DRD2 GHSR GNAS IGF1 POMC PRKAR1A
6 digestive/alimentary MP:0005381 9.98 CDH23 DRD2 GHSR MEN1 PRKAR1A SST
7 liver/biliary system MP:0005370 9.8 AIP DRD2 GNAS MEN1 POMC PRKAR1A
8 neoplasm MP:0002006 9.76 AIP DRD2 GNAS IGF1 MEN1 POMC
9 nervous system MP:0003631 9.73 CDH23 DRD2 GNAS IGF1 MEN1 POMC
10 no phenotypic analysis MP:0003012 9.23 DRD2 GHSR GNAS POMC PTTG1 SST

Drugs & Therapeutics for Pituitary Adenoma, Prolactin-Secreting

Drugs for Pituitary Adenoma, Prolactin-Secreting (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
2
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
3 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
4 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
5 Antipsychotic Agents Phase 4
6 Psychotropic Drugs Phase 4
7 Serotonin Agents Phase 4
8 Serotonin Antagonists Phase 4
9 Dopamine Antagonists Phase 4
10 Central Nervous System Depressants Phase 4
11 Tranquilizing Agents Phase 4
12
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
13
Cabergoline Approved Phase 2, Phase 3,Not Applicable 81409-90-7 54746
14
Somatostatin Approved, Investigational Phase 2, Phase 3 51110-01-1, 38916-34-6 53481605
15
Pasireotide Approved Phase 2, Phase 3 396091-73-9 9941444
16 Dopamine agonists Phase 2, Phase 3,Phase 1,Not Applicable
17 Antiparkinson Agents Phase 2, Phase 3,Phase 1,Not Applicable
18 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 1,Not Applicable
19 Sympathomimetics Phase 2, Phase 3,Phase 1,Not Applicable
20 Hormone Antagonists Phase 2, Phase 3,Phase 1
21 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1
22 Hormones Phase 2, Phase 3,Phase 1,Not Applicable
23 Autonomic Agents Phase 2, Phase 3,Phase 1,Not Applicable
24 Cardiotonic Agents Phase 2, Phase 3,Phase 1,Not Applicable
25 Protective Agents Phase 2, Phase 3,Phase 1,Not Applicable
26
Ropinirole Approved, Investigational Phase 1, Phase 2 91374-21-9, 91374-20-8 497540 5095
27
Bromocriptine Approved, Investigational Phase 2,Not Applicable 25614-03-3 31101
28
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
29
Enclomiphene Investigational Phase 2 15690-57-0
30
Lapatinib Approved March 2007, Investigational Phase 2 388082-78-8, 231277-92-2 208908 9941095
31 Selective Estrogen Receptor Modulators Phase 2
32 Estrogen Antagonists Phase 2
33 Estrogens Phase 2
34 Estrogen Receptor Modulators Phase 2
35 Zuclomiphene Phase 2
36 Estrogen Receptor Antagonists Phase 2
37 Citrate Phase 2
38 Clomiphene Phase 2
39 Fertility Agents Phase 2
40 Protein Kinase Inhibitors Phase 2
41
Curcumin Approved, Experimental, Investigational Phase 1 458-37-7 969516
42
Turmeric Approved, Experimental, Investigational Phase 1
43
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1 1177-87-3
44
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
45 Turmeric extract Phase 1
46 Analgesics Phase 1,Not Applicable
47 Anti-Inflammatory Agents, Non-Steroidal Phase 1,Not Applicable
48 Analgesics, Non-Narcotic Phase 1,Not Applicable
49 Anti-Inflammatory Agents Phase 1,Not Applicable
50 Antirheumatic Agents Phase 1,Not Applicable

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children Completed NCT01050582 Phase 4 Risperidone;Other atypical antipsychotic drugs
2 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
3 Clomiphene in Males With Prolactinomas and Persistent Hypogonadism Completed NCT00697814 Phase 2 Clomiphene citrate
4 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Recruiting NCT00939523 Phase 2 Lapatinib
5 Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Recruiting NCT03038308 Phase 1, Phase 2 Ropinirole
6 Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes Recruiting NCT02544321 Phase 2 Bromocriptine
7 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
8 Temozolomide in Treating Patients With Invasive Pituitary Tumors Withdrawn NCT00601289 Phase 2 temozolomide
9 Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients Unknown status NCT01344291 Phase 1 Curcumin
10 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
11 Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Unknown status NCT01775332 Not Applicable
12 Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas. Unknown status NCT01143584 Not Applicable Cabergoline;cabergoline
13 Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma Unknown status NCT00598949
14 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Cabergoline
15 Insulin Resistance in Women With Prolactinoma Completed NCT00481299
16 Rhinological Outcomes in Endonasal Pituitary Surgery Completed NCT01504399
17 Study on Therapy of Non-invasive Prolactinoma Recruiting NCT03353025 Not Applicable dopamine agonist treatment
18 Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus Recruiting NCT02536261
19 An Investigation of Pituitary Tumors and Related Hypothalmic Disorders Recruiting NCT00001595
20 Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA Recruiting NCT00461188
21 Seoul National University Pituitary Disease Cohort Study Recruiting NCT03474601
22 PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon Recruiting NCT02854228
23 Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors) Active, not recruiting NCT03043508
24 Long Term Outcome Study in Patients With Pituitary Disorders Active, not recruiting NCT03665064
25 Dopamine D2 Receptors(D2R) Imaging in Prolactinomas Not yet recruiting NCT03717454 Not Applicable Drug treatment
26 Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas Not yet recruiting NCT03400865 Not Applicable HCQ/CQ and CAB combined treatment
27 Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma Not yet recruiting NCT03457389 Not Applicable Cabergoline
28 Intraoperative Ultrasound in Patients Undergoing Transsphenoidal Surgery for Pituitary Adenoma Not yet recruiting NCT03284775 Not Applicable

Search NIH Clinical Center for Pituitary Adenoma, Prolactin-Secreting

Cochrane evidence based reviews: prolactinoma

Genetic Tests for Pituitary Adenoma, Prolactin-Secreting

Anatomical Context for Pituitary Adenoma, Prolactin-Secreting

MalaCards organs/tissues related to Pituitary Adenoma, Prolactin-Secreting:

41
Pituitary, Testes, Lung, Liver, T Cells, Pancreas, Thyroid

Publications for Pituitary Adenoma, Prolactin-Secreting

Articles related to Pituitary Adenoma, Prolactin-Secreting:

(show top 50) (show all 132)
# Title Authors Year
1
Prolactin-Secreting Lung Adenocarcinoma Metastatic to the Pituitary Mimicking a Prolactinoma: A Case Report. ( 30137505 )
2018
2
Nonalcoholic fatty liver disease with prolactin-secreting pituitary adenoma in an adolescent: A case report. ( 30335007 )
2018
3
Improvement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenoma. ( 29035904 )
2018
4
Giant prolactinoma, germline BRCA1 mutation, and depression: a case report. ( 30518416 )
2018
5
Endonasal chiasmapexy using autologous cartilage/bone for empty sella syndrome after cabergoline therapy for prolactinoma: A case report. ( 30315973 )
2018
6
Multiple endocrine neoplasia type 1 presenting with concurrent insulinoma and prolactinoma in early-adolescence. ( 30127804 )
2018
7
P21Waf1/Cip1 and p27Kip1 are correlated with the development and invasion of prolactinoma. ( 29230669 )
2018
8
Broad clinical spectrum and diverse outcomes of prolactinoma with pediatric onset: medication-resistant and recurrent cases. ( 29279457 )
2018
9
Characteristics of pericytes in diethylstilbestrol (DES)-induced pituitary prolactinoma in rats. ( 29344720 )
2018
10
Multiple Eyelid Cysts (Apocrine and Eccrine Hidrocystomas, Trichilemmal Cyst, and Hybrid Cyst) in a Patient With a Prolactinoma. ( 29351118 )
2018
11
The prolactin-release inhibitor paeoniflorin suppresses proliferation and induces apoptosis in prolactinoma cells via the mitochondria-dependent pathway. ( 29388711 )
2018
12
Natural and molecular history of prolactinoma: insights from a Prlr-/- mouse model. ( 29464061 )
2018
13
Medical Management of a Prolactinoma in a 15-Year-Old Girl. ( 29685620 )
2018
14
The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine. ( 29726995 )
2018
15
Long-term follow-up of female prolactinoma patients at child-bearing age after transsphenoidal surgery. ( 29934876 )
2018
16
Comparison of Male and Female Prolactinoma Patients Requiring Surgical Intervention. ( 30009121 )
2018
17
ALK7 expression in prolactinoma is associated with reduced prolactin and increased proliferation. ( 30012586 )
2018
18
18F-FDOPA Uptake Reflects the Efficacy of Dopamine Agonists Treatment in Pituitary Prolactinoma. ( 30052596 )
2018
19
Role of TGF-β1/Smad3-mediated fibrosis in drug resistance mechanism of prolactinoma. ( 30055965 )
2018
20
Estrogen receptor antagonist fulvestrant inhibits proliferation and promotes apoptosis of prolactinoma cells by regulating the IRE1/XBP1 signaling pathway. ( 30106152 )
2018
21
Cabergoline treatment in prolactinoma: amelioration in obstructive and central sleep apneas. ( 30147082 )
2018
22
Beat the giant: case of a giant prolactinoma during pregnancy on cabergoline. ( 30159146 )
2018
23
Fulvestrant inhibits the glycolysis of prolactinoma GH3 cells by downregulating IRE1/XBP1 signaling pathway. ( 30178863 )
2018
24
Atypical giant prolactinoma with frontal lobe manifestations. ( 30181411 )
2018
25
Giant Prolactinoma of Young Onset: A Clue to Diagnosis of MEN-1 Syndrome. ( 30186640 )
2018
26
Familial Cancer Clustering in Patients with Prolactinoma. ( 30196424 )
2018
27
Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up. ( 30206771 )
2018
28
DICER1 mutation and pituitary prolactinoma ( 30306785 )
2018
29
Pasireotide: A potential therapeutic alternative for resistant prolactinoma. ( 30318256 )
2018
30
Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts. ( 30334324 )
2018
31
Management of prolactinoma: a survey of endocrinologists in China. ( 30352394 )
2018
32
Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1. ( 30370446 )
2018
33
MicroRNA-93 mediates cabergoline-resistance by targeting ATG7 in prolactinoma. ( 30389900 )
2018
34
Giant Prolactinoma in Men: Clinical Features and Therapeutic Outcomes. ( 30396208 )
2018
35
Human Prolactinoma: A View of Protein-Protein Interaction Pattern. ( 30464775 )
2018
36
Direct Carotid Cavernous Fistula Due to Rupture of a Cavernous Carotid Aneurysm Embedded within a Prolactinoma after Cabergoline Administration. ( 30465960 )
2018
37
Management of dopamine agonist-resistant prolactinoma. ( 30481756 )
2018
38
Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up. ( 28954263 )
2018
39
Males with prolactinoma are at increased risk of incident cardiovascular disease. ( 29044586 )
2018
40
Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis. ( 29168011 )
2018
41
Prolactinoma through the female life cycle. ( 29177641 )
2018
42
Erratum to: Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia. ( 27854004 )
2017
43
Autoimmune hypothyroidism is three times more frequent in female prolactinoma patients compared to healthy women: data from a cross-sectional case-control study. ( 28726182 )
2017
44
Breast carcinoma associated with prolactinoma: A case report. ( 28278079 )
2017
45
Simultaneous Convexity Meningioma and Prolactinoma. ( 29204043 )
2017
46
Bilateral inferior hemifield visual loss secondary to a pituitary prolactinoma. ( 29217048 )
2017
47
Case Report of a Prolactinoma in a Patient With a Novel MAX Mutation and Bilateral Pheochromocytomas. ( 29264463 )
2017
48
Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date. ( 29381964 )
2017
49
Sex differences in the development of prolactinoma in mice overexpressing hCGβ: role of TGFβ1. ( 28096433 )
2017
50
Identification of M2 macrophages in anterior pituitary glands of normal rats and rats with estrogen-induced prolactinoma. ( 28120110 )
2017

Variations for Pituitary Adenoma, Prolactin-Secreting

ClinVar genetic disease variations for Pituitary Adenoma, Prolactin-Secreting:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 LRP2 NM_004525.2(LRP2): c.13753C> T (p.Arg4585Ter) single nucleotide variant Likely pathogenic rs202057289 GRCh37 Chromosome 2, 169985570: 169985570
2 LRP2 NM_004525.2(LRP2): c.13753C> T (p.Arg4585Ter) single nucleotide variant Likely pathogenic rs202057289 GRCh38 Chromosome 2, 169129060: 169129060

Cosmic variations for Pituitary Adenoma, Prolactin-Secreting:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM771 PIK3CA pituitary,NS,adenoma,PRL c.3073A>G p.T1025A 3:179234230-179234230 21
2 COSM760 PIK3CA pituitary,NS,adenoma,PRL c.1624G>A p.E542K 3:179218294-179218294 21
3 COSM483 HRAS pituitary,NS,adenoma,GH c.35G>T p.G12V 11:534288-534288 21
4 COSM482 HRAS pituitary,NS,adenoma,PRL c.34G>C p.G12R 11:534289-534289 21
5 COSM27887 GNAS pituitary,NS,adenoma,GH c.601C>T p.R201C 20:58909365-58909365 21
6 COSM27896 GNAS pituitary,NS,adenoma,GH c.680A>G p.Q227R 20:58909541-58909541 21
7 COSM27895 GNAS pituitary,NS,adenoma,GH c.602G>A p.R201H 20:58909366-58909366 21
8 COSM27888 GNAS pituitary,NS,adenoma,GH c.680A>T p.Q227L 20:58909541-58909541 21
9 COSM27899 GNAS pituitary,NS,adenoma,GH c.601C>A p.R201S 20:58909365-58909365 21

Expression for Pituitary Adenoma, Prolactin-Secreting

Search GEO for disease gene expression data for Pituitary Adenoma, Prolactin-Secreting.

Pathways for Pituitary Adenoma, Prolactin-Secreting

GO Terms for Pituitary Adenoma, Prolactin-Secreting

Cellular components related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.73 AIP CDH23 DRD2 GHSR GNAS PRKAR1A
2 endosome lumen GO:0031904 9.16 GH1 PRL
3 secretory granule GO:0030141 8.8 POMC PRL TRH

Biological processes related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 spermatogenesis GO:0007283 9.97 GHSR PTTG1 SSTR1 SSTR2 SSTR3
2 response to drug GO:0042493 9.92 DRD2 GNAS PRL SST
3 regulation of signaling receptor activity GO:0010469 9.91 CORT GH1 IGF1 POMC PRL SST
4 cell-cell signaling GO:0007267 9.88 POMC SST SSTR3 TRH
5 negative regulation of cell proliferation GO:0008285 9.87 DRD2 MEN1 SST SSTR1 SSTR2 SSTR3
6 response to ethanol GO:0045471 9.8 DRD2 PRL TRH
7 response to estradiol GO:0032355 9.79 GH1 GHSR PRL
8 female pregnancy GO:0007565 9.78 GHSR GNAS PRL
9 forebrain development GO:0030900 9.76 DRD2 SSTR1 SSTR2 SSTR3
10 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.73 SSTR1 SSTR2 SSTR3 SSTR5
11 G protein-coupled receptor signaling pathway GO:0007186 9.73 CORT DRD2 GHSR GNAS POMC SST
12 cerebellum development GO:0021549 9.72 SSTR1 SSTR2 SSTR3
13 cellular response to estradiol stimulus GO:0071392 9.7 SSTR1 SSTR2 SSTR3
14 positive regulation of multicellular organism growth GO:0040018 9.69 DRD2 GH1 GHSR
15 response to starvation GO:0042594 9.67 SSTR1 SSTR2 SSTR3
16 cellular response to glucocorticoid stimulus GO:0071385 9.65 SSTR2 SSTR3 SSTR5
17 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.6 GH1 PRL
18 positive regulation of growth GO:0045927 9.59 GH1 GHSR
19 peristalsis GO:0030432 9.58 DRD2 SSTR2
20 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.58 GH1 GHSR IGF1
21 postsynaptic modulation of chemical synaptic transmission GO:0099170 9.56 DRD2 GHSR
22 neuropeptide signaling pathway GO:0007218 9.55 POMC SSTR1 SSTR2 SSTR3 SSTR5
23 hormone-mediated apoptotic signaling pathway GO:0008628 9.54 SST SSTR3
24 somatostatin signaling pathway GO:0038170 8.92 SSTR1 SSTR2 SSTR3 SSTR5
25 signal transduction GO:0007165 10 DRD2 GHSR GNAS IGF1 POMC SSTR1

Molecular functions related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.85 DRD2 GHSR SSTR1 SSTR2 SSTR3 SSTR5
2 G protein-coupled receptor binding GO:0001664 9.5 CORT GNAS POMC
3 neuropeptide binding GO:0042923 9.46 SSTR1 SSTR2 SSTR3 SSTR5
4 insulin-like growth factor receptor binding GO:0005159 9.4 GNAS IGF1
5 prolactin receptor binding GO:0005148 9.26 GH1 PRL
6 somatostatin receptor activity GO:0004994 9.26 SSTR1 SSTR2 SSTR3 SSTR5
7 hormone activity GO:0005179 9.17 CORT GH1 IGF1 POMC PRL SST

Sources for Pituitary Adenoma, Prolactin-Secreting

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....